Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Hormonal Mechanisms of Perimenopausal Risk for Psychosis in Women

Award Number: R01MH128196
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2022
PERIOD OF PERFORMANCE END DATE: 01/31/2027

Group Awards By:

View Award Description

Hormonal Mechanisms of Perimenopausal Risk for Psychosis in Women - PROJECT SUMMARY Women show a heightened risk for psychosis in midlife that is not observed in men. The menopausal transition (i.e., perimenopause) is presumed to account for these midlife changes in risk, but data examining this possibility are wholly lacking. Information on mechanisms of midlife risk is largely absent as well. Ovarian hormones are key to menopausal changes in women and are known to have wide-reaching effects on brain and behavior. Thus, it has been theorized that changes in these hormones during perimenopause drive midlife psychosis risk in women, and studies during other reproductive events (e.g., the menstrual cycle) show increased psychotic symptoms in women with lower levels of ovarian hormones. However, to date, no studies have examined if changes in ovarian hormones are mechanisms of midlife psychosis risk in women. Consequently, the Specific Aims of the proposed project are to isolate the perimenopausal period as a critical period of risk (Aim 1) and examine ovarian hormones as mechanisms of effects (Aim 2). We will address these aims using an innovative, multi-method (behavioral, neuroendocrine, multi-informant), and intensive daily study design in a large, population-based sample of women (N = 750) that varies in menopausal status (i.e., premenopause, perimenopause, postmenopause) and is enriched for psychosis risk. Women will collect daily data on psychotic (and related) symptoms across 35 consecutive days, and we will use these data to confirm that perimenopausal stage, rather than age or other factors (e.g., midlife stress), drive increased psychosis risk in women (Aim 1). We will then extend these data by collecting daily saliva samples of estrogen and progesterone across the 35-day study period in the perimenopausal women and examining whether levels and changes in these hormones are mechanisms underlying midlife psychosis risk in women (Aim 2). We will assess a range of psychotic symptoms across the study period to capture the full spectrum of psychosis risk, and we will collect informant and clinician symptom ratings to validate and confirm symptom reports. Importantly, our proposed study addresses the RFA high priority area “Research clarifying the mechanistic role of reproductive steroids in generating, moderating, or mitigating mood and psychosis symptoms during the menopausal transition.” Indeed, our novel, longitudinal study will allow us to quantify population- level risk for midlife psychosis as well as elucidate the critical hormonal mechanisms that are necessary to inform women's health policy and devise translational approaches to prevention and intervention.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $680,693 )
2026	2026	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 360	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	5	2/13/2026	NON-COMPETING CONTINUATION	$680,693
														Subtotal = $680,693

Issue Date FY: 2025 ( Subtotal = $589,738 )
2025	2025	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	4	1/22/2025	NON-COMPETING CONTINUATION	$589,738
														Subtotal = $589,738

Issue Date FY: 2024 ( Subtotal = $746,216 )
2024	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	001	3	6/14/2024	NON-COMPETING CONTINUATION	$74,621
2024	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	3	1/25/2024	NON-COMPETING CONTINUATION	$671,595
														Subtotal = $746,216

Issue Date FY: 2023 ( Subtotal = $744,882 )
2023	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	2	2/2/2023	NON-COMPETING CONTINUATION	$744,882
														Subtotal = $744,882

Issue Date FY: 2022 ( Subtotal = $785,469 )
2022	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	1	1/28/2022	NEW	$785,469
														Subtotal = $785,469

Grand Total All Awards = $3,546,998

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Hormonal Mechanisms of Perimenopausal Risk for Psychosis in Women

Award Number: R01MH128196

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2022

PERIOD OF PERFORMANCE END DATE: 01/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer